Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

RIGL Rigel Pharmaceuticals Inc

19,70

-0,59 (-2,91%)

06 Mär 2025 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/24/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Esteban Masuda

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Rigel Pharmaceuticals Charts.

Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Rigel Pharmaceuticals Charts.

News Rigel Pharmaceuticals Inc

Form 8-K - Current report
Dienstag 4 März 2025 (2 Tage vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 4 März 2025 (2 Tage vor) • Edgar (US Regulatory)

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dienstag 4 März 2025 (2 Tage vor) • PR Newswire (US)

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Dienstag 25 Februar 2025 (1 Woche vor) • PR Newswire (US)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 14 Februar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 5 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 5 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 5 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Weitere Rigel Pharmaceuticals Inc News-Artikel

iShares USD High Yield C...

BNP Paribas Issuance

Lyxor Stoxx Europe 600 B...

SPDR DoubleLine Total Re...

ABN Amro Bank NV 1.171% ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen